All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubLymphoma HubMDS HubMPN HubMultiple Myeloma

What do you think are the most promising new drugs in the treatment of steroid-refractory cGvHD?

During the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), the GvHD hub was pleased to speak to Zinaida Peric, University of Zagreb, Zagreb, HR. We asked, What do you think are the most promising new drugs in the treatment of steroid-refractory cGvHD?

What do you think are the most promising new drugs in the treatment of steroid-refractory cGvHD?

In this video, Peric discusses the advances in new oral agents, belumosudil and ruxolitinib, for the treatment of steroid-refractory chronic graft-versus-host disease. She also mentions the earlier drug, ibrutinib.

 

Share: